



GIG
CYMRU
NHS
WALES

Bwrdd Iechyd Prifysgol
Cwm Taf Morgannwg
University Health Board



Freedom of Information Request: Our Reference CTMUHB_503_24

You asked:

I have a freedom of information request.

1. Please provide the number of migraine patients treated in the last 4 months with:

- **Atogepant (Aquipta)**
- **Erenumab (Aimovig)**
- **Eptinezumab (Vyepti)**
- **Fremanezumab (Ajovy)**
- **Galcanezumab (Emgality)**
- **Rimegepant (Vydura)**
- **Botulinum Toxin (i.e., Botox, Dysport, Xeomin)**

Please find below the information Medicines Management are able to provide at this current time. The period the data relates to is the latest available; number of patients and number of issues Secondary Care is 1st June 2024 to 30th September 24; WP10's number of issues and Primary Care number of issues is 1st April 24 to 31st July 24.

Where the number of issues has been supplied, we are unable to provide the number of patients due to this level of detail not being available. Unfortunately, not all issues in Secondary Care issued out by individual patient name some are supplied to ward areas as stock. Again, in relation to WP10's and Primary Care number of issues has been supplied due to patient information not being readily available.

Medicine	Number of Patients Secondary Care		
Atogepant (Aquipta)	13		
Erenumab (Aimovig)	8		
Eptinezumab (Vyepti)	0		
Fremanezumab (Ajovy)	40		
Galcanezumab (Emgality)	12		
Rimegepant (Vydura)	11		
Medicine	Number of Issues Secondary Care	WP10's number of Items	Primary Care Number of Items

Rimegepant (Vydura)		5	55
Botulinum Toxin (i.e., Botox, Dysport, Xeomin)	290		

2. How many patients have you treated in the last 4 months for acute migraine with:

- **Rimegepant (Vydura)**

Unfortunately, we are unable to provide the number of patients that have been specifically treated with Rimegepant for acute migraine because the pharmacy systems do not record this information and it is not captured centrally.

3. Are you required to complete Blueteq for the following product classes:

- **Botulinum Toxin (Botox, Dysport, Xeomin)**
- **Monoclonal antibodies (e.g. fremanezumab, erenumab, galcanezumab, eptinezumab)**
- **Gepants (e.g. rimegepant, atogepant)**

The Cwm Taf Morgannwg University Health Board has only recently started the implementation process of BlueTeq. When fully implemented it would be expected that a BlueTeq criteria will be completed for all high cost medicines that appear on the All Wales High Cost Drugs List (in the process of being agreed). We anticipate the medicines mentioned above in question three will be included on the All Wales High Cost Drugs List.